All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VBI-2901
Therapeutic Area: Infections and Infectious Diseases Product Name: VBI-2901
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: VBI Vaccines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 18, 2020
Details:
Under the terms of the agreement, Therapure will be responsible for the biomanufacturing of the vaccine drug substance as well as the aseptic fill of the drug product at the Therapure facility in Mississauga, Ontario, Canada.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Yeast beta-glucans
Therapeutic Area: Infections and Infectious Diseases Product Name: PGX-YBG
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2020
Details:
In-vitro study with human cell lines demonstrated that PGX-YBG obtained from different sources exhibited significant stimulatory effect on human immune response.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KG2019
Therapeutic Area: Infections and Infectious Diseases Product Name: KG2019
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Government of Canada
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 14, 2020
Details:
The goal of this therapeutic platform is to both prevent SARS-Cov2 cellular invasion into these tissues (‘viral trap’) and to mitigate pathology triggered by the host response to the virus, including over-activation of immune system and lung and heart failure.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2020
Details:
Company has commenced two pre-clinical trials designed to demonstrate the efficacy of its proprietary Quicksome™ technology in overcoming key absorption limitations of the oral drug Ivermectin and report pharmacokinetic results of Quicksome™ oral strip sublingual technology.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Zileuton,Montelukast
Therapeutic Area: Infections and Infectious Diseases Product Name: Zyflo
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2020
Details:
Novateur proposes a simple treatment paradigm using a combination of a leukotriene biosynthesis blocker, Zyflo® controlled release formulation and an inhibitor of the cysteinyl leukotriene 1 receptor, Singulair® to target the hyper-inflammatory response insevere COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DPX-COVID-19
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: NRC IRAP
Deal Size: $3.5 million Upfront Cash: Undisclosed
Deal Type: Funding August 04, 2020
Details:
Fundng will support advancement of IMV's Phase 1 clinical development of its vaccine candidate, DPX-COVID-19, for the prevention of COVID-19 infection caused by the novel coronavirus SARS-COV-2.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IgY-110
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: MMS Holdings
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 08, 2020
Details:
The partnership aims at further developing IgY-110, an anti-CoV-2 therapeutic antibody with a focus on a nasal spray application. This novel approach of an IgY antibody in a nasal spray will be complementary to any vaccine developed.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
An additional step will be to proceed with an open-label study to assess the safety and efficacy of a clinical course of oral apabetalone in hospitalized subjects with 2019-nCoV infection on top of standard of care compared to standard of care alone.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DPX-COVID-19
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020
Details:
Majority of 23 peptide epitopes selected by IMV demonstrated robust antibody responses in an animal model after first and second dose in DPX formulation without any additional adjuvant.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cannabidiol
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2020
Details:
Tetra Bio-Pharma has completed the modifications to the nonclinical safety study of PPP003 to ensure the launch of a Phase 1 trial in healthy volunteers.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
